No quarterly revenue total was found in Kailera Therapeutics, Inc.'s SEC filings.
Kailera Therapeutics, Inc. (KLRA) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$133.7 million. As of Sep 30, 2026 it held $1.0 billion in cash and investments and $10.0 million in total debt.
Revenue
—
Net income
$-95.67M
+14.1% vs prior quarter
Operating cash flow
$-133.67M
-72.4% vs prior quarter
Free cash flow
$-133.67M
EPS
$-0.74
+32.1% vs prior quarter
Dividend per share
None
Shares outstanding
129.85M
+0.2% vs prior quarter
Net cash
$1.03B
Q3 FY2026
Operating margin
—
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- KLRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Waltham, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 2096997
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
|---|---|---|---|
| Operating income | -$106.3M | -$121.4M | -$84.7M |
| Net income | -$95.7M | -$111.3M | -$78.9M |
| Diluted EPS | -$0.74 | -$1.09 | -$3,650.00 |
| Operating cash flow | -$133.7M | -$77.5M | -$68.3M |
| Free cash flow | -$133.7M | — | — |
| Total assets | $1.1B | $1.2B | $624.8M |
| Total liabilities | $51.1M | $93.0M | $64.5M |
| Stockholders' equity | $1.0B | $1.1B | -$432.1M |
| Cash and investments | $1.0B | $1.2B | $581.9M |
| Total debt | $10.0M | $10.2M | $10.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 10-Q | Quarterly report | Aug 12, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2026 | Aug 12, 2026 |
| 10-Q | Quarterly report | May 26, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 26, 2026 | May 26, 2026 |
All 64 Kailera Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.